Document:

Form of Third Amendment and Consent to Amended and Restated Credit Agreement

 Exhibit 4.1 
 EXECUTION COPY 
 THIRD AMENDMENT AND CONSENT 
 TO AMENDED AND RESTATED CREDIT AGREEMENT 
 THIS THIRD AMENDMENT AND CONSENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”), dated as of July 14, 2008, is entered into among Owens & Minor Medical, Inc. and Owens & Minor
Distribution, Inc. (the “Borrowers”), Owens & Minor, Inc. (the “Parent”), certain subsidiaries of the Parent party hereto (together with the Parent, the “Guarantors”), the banks identified
on the signature pages hereto (the “Banks”) and Bank of America, N.A., as Administrative Agent. Terms used but not otherwise defined herein shall have the meanings provided in the Credit Agreement described below. 
 W I T N E S S E T H 
 WHEREAS,
the Borrowers, the Parent, the other Guarantors, the Banks party thereto, and the Administrative Agent entered into that certain Amended and Restated Credit Agreement dated as of May 4, 2004 (as amended by that certain First Amendment dated as
of April 3, 2006, as amended by that certain Second Amendment dated as of January 29, 2007 and as may be further amended, restated, supplemented or otherwise modified from time to time, the “Existing Credit Agreement”);

 WHEREAS, the Borrowers have requested, and the Required Banks have agreed, to amend the Existing Credit Agreement as provided
herein; and 
 NOW, THEREFORE, in consideration of the agreements hereinafter set forth, and for other good and valuable
consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows: 
 PART 1 
 DEFINITIONS 
 SUBPART 1.1
Certain Definitions. Unless otherwise defined herein or the context otherwise requires, the following terms used in this Amendment, including its preamble and recitals, have the following meanings: 
 “Amended Credit Agreement” means the Existing Credit Agreement as amended hereby. 
 “Third Amendment Effective Date” is defined in Subpart 4.1. 

 SUBPART 1.2 Other Definitions. Unless otherwise defined herein or the context otherwise
requires, terms used in this Amendment, including its preamble and recitals, have the meanings provided in the Existing Credit Agreement. 
 PART 2 
 AMENDMENTS TO EXISTING CREDIT AGREEMENT 
 Effective on (and subject to the occurrence of) the Third Amendment Effective Date, the Existing Credit Agreement is hereby amended in accordance with
this Part 2. 
 SUBPART 2.1 Section 1.1 of the Existing Credit Agreement is hereby amended by adding the following
definitions of “Additional Commitment Bank”, “Existing Termination Date”, “Extension Date”, “Extending Bank”, ““Increase Effective Date”, “Investment
Grade”, “Non-Consenting Bank”, “Non-Extending Bank” “Notice Date” “Permitted Asset Swap” and “Third Amendment Effective Date” in appropriate alphabetical
order: 
 “Additional Commitment Bank” has the meaning set forth in Section 2.11(d). 
 “Existing Termination Date” has the meaning set forth in Section 2.11(a). 
 “Extending Bank” has the meaning set forth in Section 2.11(e). 
 “Extension Date” has the meaning set forth in Section 2.11(a). 
 “Increase Effective Date” has the meaning set forth in Section 2.10. 
 “Investment Grade” means a senior unsecured long term debt rating of at least Baa3 from Moody’s and BBB- from S&P. 

“Non-Consenting Bank” has the meaning set forth in Section 11.18. 
 “Non-Extending Bank” has the meaning set forth in Section 2.11(b). 
 “Notice Date” has the meaning set forth in Section 2.11(b). 
 “Permitted Asset Swap” means any transfer of properties or assets by any member of the Consolidated Group in which at least 90% of the
consideration received by the transferor consists of properties or assets (other than cash) that will be used in a business that is related, ancillary or complementary to the business of the Borrowers or any of their Subsidiaries on the Third
Amendment Effective Date (or any reasonable extension, development or expansion thereof); provided that the aggregate fair market value (as determined in good faith by the Board of Directors of the relevant Credit Party) of the property or assets
transferred in such exchange is not greater than that of the assets or property received. 
  

 2 

 “Third Amendment Effective Date” means July 14, 2008. 
 SUBPART 2.2 The definition of “Eligible Inventory” set forth in Section 1.1 of the Existing Credit Agreement is hereby
deleted in its entirety. 
 SUBPART 2.3 The definition of “Extension of Credit” set forth in Section 1.1
of the Existing Credit Agreement is hereby amended by replacing such definition in its entirety with the following: 
 “Extension of Credit” means, as to any Bank, the making of, or participation in, a Loan by such Bank or the issuance or extension of, or participation in, a Letter of Credit by such Bank. 
 SUBPART 2.4 The definition of “Permitted Investments” set forth in Section 1.1 of the Existing Credit Agreement is hereby
amended by replacing subsection (viii) of such definition in its entirety with the following: 
 (viii) Investments of a
nature not contemplated in the foregoing subsections; provided, however, to the extent that the Consolidated Total Leverage Ratio on a Pro Forma Basis after giving effect to any such Investment is greater than 2.25:1.00, the aggregate amount
of such Investments permitted pursuant to the clause (viii) shall not exceed the greater of (A) the Investments permitted under this clause (viii) and made prior to the date that the Consolidated Total Leverage Ratio referred to in
this clause (viii) exceeded 2.25:1.00 and (B) $15,000,000 in the aggregate at any time outstanding. 
 SUBPART 2.5 The
definition of “Permitted Liens” set forth in Section 1.1 of the Existing Credit Agreement is hereby amended by (a) deleting “and” from the end of clause (xv) of such Section, (b) renumbering clause
(xvi) of such Section to (xviii) and (c) adding the following as the new clauses (xvi) and (xvii) of such Section: 
 (xvi) Liens on real property located at 9120 Lockwood Boulevard, Mechanicsville, Virginia 23116 owned by Owens & Minor Medical, Inc. secured by a mortgage not to exceed $40,000,000 in the aggregate at any one
time outstanding; 
 (xvii) other Liens on Property of any Person securing Indebtedness of any member of the Consolidated
Group not to exceed $25,000,000 in the aggregate at any one time outstanding; and 
 SUBPART 2.6 The definition of “Pro Forma
Basis” set forth in Section 1.1 of the Existing Credit Agreement is hereby amended by replacing subsection (iv) of such definition in its entirety with the following: 
 (iv) any Investment permitted by clause (viii) of the definition of Permitted Investments and 
  

 3 

 SUBPART 2.7 The definition of “Responsible Officer” set forth in Section 1.1
of the Existing Credit Agreement is hereby amended by replacing such definition in its entirety with the following: 
 “Responsible Officer” means, with respect to the subject matter of any representation, warranty, covenant, agreement, obligation or certificate of any Credit Party contained in or delivered pursuant to any of the Credit
Documents, the Chief Executive Officer, the President, Executive Vice President, Chief Financial Officer, Controller, General Counsel or Treasurer of the Borrower or the Parent. 
 SUBPART 2.8 The definition of “Senior Subordinated Notes” set forth in Section 1.1 of the Existing Credit Agreement is
hereby amended by replacing such definition in its entirety with the following: 
 “Senior Subordinated
Notes” means those $200,000,000 8.5% Senior Subordinated Notes of the Parent due 2011 that were paid in full on or about April 15, 2006. 
 SUBPART 2.9 Amendment to Section 2.1(b). Subsection (b) of Section 2.1 of the Existing Credit Agreement is hereby amended by deleting the reference to “FIFTY MILLION DOLLARS
($50,000,000)” and replacing it with “SEVENTY-FIVE MILLION DOLLARS ($75,000,000)”.  
 SUBPART 2.10 Amendment
to Section 2. Section 2 of the Existing Credit Agreement is hereby amended to add the following as Subsection 2.10: 
 2.10
Increase in Commitments. 
 (a) Request for Increase. Provided there exists no Default, upon notice to the
Administrative Agent (which shall promptly notify the Banks), the Borrowers may from time to time, request an increase in the aggregate Commitments by an amount (for all such requests) not exceeding $100,000,000; provided that (i) any
such request for an increase shall be in a minimum amount of $25,000,000, and (ii) the Borrowers may make a maximum of three such requests. At the time of sending such notice, the Borrowers (in consultation with the Administrative Agent) shall
specify the time period within which each Bank is requested to respond (which shall in no event be less than ten Business Days from the date of delivery of such notice to the Banks). 
 (b) Bank Elections to Increase. Each Bank shall notify the Administrative Agent within such time period whether or not it agrees to
increase its Commitment and, if so, whether by an amount equal to, greater than, or less than its pro rata share of such requested increase. Any Bank not responding within such time period shall be deemed to have declined to increase its Commitment.

 (c) Notification by Administrative Agent; Additional Banks. The Administrative Agent shall notify the Borrowers and
each Bank of the Banks’ responses to each request made hereunder. To achieve the full amount of a requested increase and 

  

 4 

 
subject to the approval of the Administrative Agent, the Issuing Bank and the Swingline Bank (which approvals shall not be unreasonably withheld), the
Borrowers may also invite additional Eligible Assignees to become Banks pursuant to a joinder agreement in form and substance reasonably satisfactory to the Administrative Agent and its counsel. 
 (d) Effective Date and Allocations. If the aggregate Commitments are increased in accordance with this Section, the Administrative
Agent and the Borrowers shall determine the effective date (the “Increase Effective Date”) and the final allocation of such increase. The Administrative Agent shall promptly notify the Borrowers and the Banks of the final allocation
of such increase and the Increase Effective Date. 
 (e) Conditions to Effectiveness of Increase. As a condition
precedent to such increase, the Borrowers shall deliver to the Administrative Agent a certificate of each Credit Party dated as of the Increase Effective Date (in sufficient copies for each Bank) signed by the Chief Executive Officer, the President,
Executive Vice President, Chief Financial Officer, Controller, General Counsel or Treasurer of such Credit Party (i) certifying and attaching the resolutions adopted by such Credit Party approving or consenting to such increase, and
(ii) in the case of the Borrowers, certifying that, before and after giving effect to such increase, (A) the representations and warranties contained in Section VI and the other Credit Documents are true and correct in all material
respects on and as of the Increase Effective Date, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct in all material respects as of such earlier date, and
except that for purposes of this Section 2.10, the representations and warranties contained in subsections (a) and (b) of Section 6.7 shall be deemed to refer to the most recent statements furnished pursuant to
clauses (a) and (b), respectively, of Section 7.1, and (B) no Default exists. The Borrowers shall prepay any Loans outstanding on the Increase Effective Date (and pay any additional amounts required pursuant to
Section 3.12) to the extent necessary to keep the outstanding Loans ratable with any revised percentage of the Banks’ Commitments arising from any nonratable increase in the Commitments under this Section. 
 (f) Conflicting Provisions. This Section shall supersede any provisions in Section 3.14 or 11.6 to the contrary.

 SUBPART 2.11 Amendment to Section 2. Section 2 of the Existing Credit Agreement is hereby amended to add
the following as Subsection 2.11: 
 2.11 Extension of Termination Date. 
 (a) Requests for Extension. The Borrower may, by notice to the Administrative Agent (who shall promptly notify the Banks) not later
than 120 days prior to the Termination Date (the “Extension Date), request that each Bank extend such Bank’s Termination Date for an additional year from the Termination Date then in effect hereunder (the “Existing
Termination Date”). 
 (b) Bank Elections to Extend. Each Bank, acting in its sole and individual discretion,
shall, by notice to the Administrative Agent given not later than the date (the 

  

 5 

 
“Notice Date”) that is 15 Business Days from the date which such Bank received notice from the Administrative Agent of the Borrower’s
request for an extension of the Existing Termination Date, advise the Administrative Agent whether or not such Bank agrees to such extension. Each Bank that determines not to so extend its Termination Date (a “Non-Extending Bank”)
shall notify the Administrative Agent of such fact promptly after such determination (but in any event no later than the Notice Date), and any Bank that does not so advise the Administrative Agent on or before the Notice Date shall be deemed to be a
Non-Extending Bank. The election of any Bank to agree to such extension shall not obligate any other Bank to so agree. 
 (c)
Notification by Administrative Agent. The Administrative Agent shall notify the Borrower of each Bank’s determination under this Section 2.11 no later than the date 15 days prior to the applicable Extension Date (or, if such date is
not a Business Day, on the next preceding Business Day). 
 (d) Additional Commitment Banks. The Borrower shall have
the right on or before the Extension Date (effective as of the Extension Date) to replace the Commitments of any Non-Extending Banks with, and at its option add as “Banks” under this Agreement, one or more Eligible Assignees (each,
an “Additional Commitment Bank”) as provided in Section 11.18, each of which Additional Commitment Banks shall have entered into an Assignment and Assumption pursuant to which such Additional Commitment Bank shall, effective as
of the applicable Extension Date, undertake a Commitment (and, if any such Additional Commitment Bank is already a Bank, its Commitment shall be in addition to such Bank’s Commitment hereunder on such date). 
 (e) Minimum Extension Requirement. If (and only if) the total of the Commitments of the Banks that have agreed so to extend their
Termination Date (each, an “Extending Bank”) and the additional Commitments of the Additional Commitment Banks shall be more than 50% of the aggregate amount of the Commitments in effect immediately prior to the applicable Extension
Date, then, effective as of such Extension Date, the Termination Date of each Extending Bank and of each Additional Commitment Bank shall be extended to the date falling one year after the Existing Termination Date (except that, if such date is not
a Business Day, such Termination Date as so extended shall be the next preceding Business Day) and each Additional Commitment Bank shall thereupon become a “Bank” for all purposes of this Agreement; provided, however,
that there shall be no change in the Termination Date of any Non-Extending Bank. 
 (f) Conditions to Effectiveness of
Extensions. Notwithstanding the foregoing, the extension of the Termination Date pursuant to this Section shall not be effective with respect to any Bank unless: 
 (i) no Default exists on the date of such extension and after giving effect thereto; 
 (ii) the representations and warranties contained in Article VI and the other Loan Documents are true and correct in all material respects
on and as of 

  

 6 

 
the Extension Date, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and
correct in all material respects as of such earlier date; and 
 (iii) to the extent the Commitments of any Non-Extending Bank
shall not be replaced with Commitments from one or more Additional Commitment Banks on the applicable Extension Date as provided for in Section 2.11(d), and thus there shall be no change in the applicable Termination Date for such Non-Extending
Bank, it is understood and agreed that (x) the Borrower shall repay Loans outstanding on the applicable Termination Date of any such Non-Extending Bank (and pay any additional amounts required pursuant to Section 3.12) to the extent
necessary to repay, nonratably, the Loans of all Non-Extending Banks and the pro rata shares of the remaining Banks shall be revised effective as of such date, (y) on such applicable Termination Date, the Commitments of the Non-Extending Banks
will be permanently terminated and the Aggregate Commitments on and after such date will be equal to the Commitments of the remaining Banks and (z) to the extent that the outstanding Obligations as of such date (after giving effect to the
repayment in full of each such Non-Extending Bank) exceed the Aggregate Commitments then in effect (after giving effect to the termination of the Commitments of all Non-Extending Banks), the Borrower shall immediately prepay Loans and/or cash
collateralize the LOC Obligations in an aggregate amount equal to such excess. 
 (g) Conflicting Provisions. This
Section shall supersede any provisions in Section 3.14 and Section 11.6 to the contrary. 
 SUBPART 2.12 Amendment to
Section 3.2. The third sentence of Section 3.2 of the Existing Credit Agreement is hereby amended in its entirety to read as follows: 
 Each request for extension or conversion to any Eurodollar Loan shall be deemed to be a reaffirmation by the Borrower Representative that no Default or Event of Default then exists. 
 SUBPART 2.13 Amendment to Section 3.17(c). Subsection (c) of Section 3.17 of the Existing Credit Agreement is hereby amended
in its entirety to read as follows: 
 (c) RESERVED. 
 SUBPART 2.14 Amendment to Section 5.2. Section 5.2 of the Existing Credit Agreement is hereby amended by replacing Subsection (a) and the last paragraph of Section 5.2 of the Existing
Credit Agreement in their entireties with the following: 
 (a) Representations and Warranties. The representations and
warranties made by the Credit Parties herein and in the other Credit Documents and which are contained in any certificate furnished at any time under or in connection herewith shall be true and correct in all material respects on and as of the date
of such Extension of Credit as if made on and as of such date (except for those which expressly relate to an earlier date); 

  

 7 

 
provided, however, the representations and warranties contained in Sections 6.8 (No Material Adverse Changes or Restricted Payments), 6.16
(ERISA) and 6.20 (Environmental Matters) shall only be required to be true and correct in all material respects on and as of the Closing Date and the Increase Effective Date. 
 ***** 
 Each request for an Extension of Credit and each acceptance by
the Borrower Representative of an Extension of Credit shall be deemed to constitute a representation and warranty by the Borrower Representative as of the date of such Extension of Credit that the applicable conditions in paragraphs (a),
(b) and (c) of this Section 5.2 have been satisfied. 
 SUBPART 2.15 Amendment to Section 6.12.
Section 6.12 of the Existing Credit Agreement is hereby amended by deleting the last sentence of such section. 
 SUBPART 2.16
Amendment to Section 7.1(f). Subsection (f) of Section 7.1 of the Existing Credit Agreement is hereby amended in its entirety to read as follows: 
 (f) SEC and Other Material Reports. Promptly upon transmission or receipt thereof, (i) copies of all registration statements
(excluding the exhibits thereto and any registration statements on Form S-8 or its equivalent), reports on Forms 10-K, 10-Q and 8-K (or their equivalents) and all other periodic reports which any member of the Consolidated Group shall file with the
Securities and Exchange Commission, or any successor agency and (ii) copies of all material reports and written information to and from the United States Environmental Protection Agency, or any state or local agency responsible for
environmental matters, the United States Occupational Health and Safety Administration, or any state or local agency responsible for health and safety matters, or any successor agencies or authorities concerning environmental, health or safety
matters. 
 Documents required to be delivered pursuant to Section 7.01(f) (to the extent any such documents are included in materials
otherwise filed with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date (i) on which the Parent posts such documents, or provides a link thereto on the Parent’s website on the
Internet at http://owens-minor.com or any other website address provided to the Administrative Agent by the Parent; or (ii) on which such documents are posted on the Parent’s behalf on an Internet or intranet website, if any, to which each
Lender and the Administrative Agent have access (whether a commercial, third-party website or sponsored by the Administrative Agent); provided that the Parent shall notify the Administrative Agent (by telecopier or electronic mail) of the
posting of any such documents and, upon the Administrative Agent’s request, provide to the Administrative Agent by electronic mail electronic versions (i.e., soft copies) of such documents. The Administrative Agent shall have no
obligation to request the delivery or to maintain copies of the documents referred to above, and in any event shall have no responsibility to monitor compliance by the Company with any such request for delivery, and each Lender shall be solely
responsible for maintaining its copies of such documents. 
  

 8 

 SUBPART 2.17 Amendment to Section 7.10(b). Subsection (b) of
Section 7.10 of the Existing Credit Agreement is hereby amended in its entirety to read as follows: 
 (b)
Consolidated Total Leverage Ratio. As of the end of each fiscal quarter of the Parent, the Consolidated Total Leverage Ratio shall not be greater than 3.50:1.0. 
 SUBPART 2.18 Amendment to Section 7.11(a). Subsection (a) of Section 7.11 of the Existing Credit Agreement is hereby amended in its entirety to read as follows: 
 (a) Additional Subsidiaries. If upon the delivery of the financial statements pursuant to Section 7.01(b), the Non-Guarantor
Subsidiaries (other than Owens & Minor Healthcare Supply Inc. and Access Diabetic Supply, LLC) shall, as a group, (i) account for more than five percent (5%) of the gross revenues of the members of the Consolidated Group on a
consolidated basis determined in accordance with GAAP, (ii) account for more than five percent (5%) of net income of the members of the Consolidated Group on a consolidated basis determined in accordance with GAAP, or (iii) constitute
more than five percent (5%) of Consolidated Total Assets (each a “Threshold Requirement”), then the Borrower Representative will (A) promptly notify the Administrative Agent and the Banks thereof, (B) within 45 days
thereafter, cause one or more of the Non-Guarantor Subsidiaries to become a “Guarantor” hereunder by way of execution of a Joinder Agreement such that immediately thereafter the remaining Non-Guarantor Subsidiaries shall not, as a group,
exceed any Threshold Requirement and (C) deliver such other documentation as the Administrative Agent may reasonably request in connection with the foregoing, including, without limitation, certified resolutions and other organizational and
authorizing documents of such Person, good standing certificates and favorable opinions of counsel to such Person, all in form, content and scope reasonably satisfactory to the Administrative Agent. The Borrower Representative may at any time, at
its option, cause a Non-Guarantor Subsidiary to execute and deliver to the Administrative Agent a Joinder Agreement. 
 SUBPART 2.19
Amendment to Section 8.1(d). Subsection (d) of Section 8.1 of the Existing Credit Agreement is hereby amended in its entirety to read as follows: 
 (d) RESERVED. 
 SUBPART 2.20
Amendment to Section 8.1(h). Subsection (h) of Section 8.1 of the Existing Credit Agreement is hereby amended in its entirety to read as follows: 
 (h) other unsecured Funded Debt of the members of the Consolidated Group which does not exceed $275,000,000 in the aggregate at any time
outstanding; 
 SUBPART 2.21 Amendment to Section 8.1(k). Subsection (k) of Section 8.1 of the Existing
Credit Agreement is hereby amended in its entirety to read as follows: 
 (k) other secured Indebtedness of any member of the
Consolidated Group which does not exceed $25,000,000 in the aggregate at any time outstanding. 
  

 9 

 SUBPART 2.22 Amendment to Section 8.4(b)(ii)(B)(VIII). Subsections (VII) and
(VIII) of Section 8.4(b)(ii)(B) of the Existing Credit Agreement is hereby amended in their entirety to read as follows: 
 (VII)
RESERVED; and 
 (VIII) in the case of the Acquisition of Property and Acquisitions of Capital Stock of any Person, unless the
Borrower Representative has delivered to the Administrative Agent a Pro Forma Compliance Certificate demonstrating that the Consolidated Total Leverage Ratio on a Pro Forma Basis after giving effect to any such Acquisition is less than 3.00:1.0, the
Total Consideration paid in connection with any such Acquisition (or series of related Acquisitions) shall not exceed $50,000,000. 
 SUBPART 2.23 Amendment to Section 8.5(iii). Subsection (iii) of Section 8.5 of the Existing Credit Agreement is hereby amended in its entirety to read as follows: 
 (iii) in all other cases, 
 (A) other than in connection with a Permitted Asset Swap, at least seventy-five percent (75%) of the consideration paid therefor shall consist of a combination of (i) cash or Cash Equivalents, (ii) the
assumption by the purchaser of liabilities of the Credit Parties (other than liabilities that are by their terms subordinated to the prior payment of the Obligations) as a result of which the Credit Parties are no longer obligated with respect to
such liabilities, or (iii) any securities, notes, obligations or other assets received by the Credit Parties that are converted by the Credit Parties into cash (to the extent of the cash received) within 90 days after receipt, 
 (B) to the extent that the Parent (x) is not rated at least Investment Grade, the aggregate net book value of all Asset
Dispositions (including, without limitation, pursuant to a Permitted Asset Swap) in any fiscal year shall not exceed an amount equal to twenty percent (20%) of Consolidated Total Assets as of the end of the immediately preceding fiscal year and
(y) is rated at least Investment Grade, Asset Dispositions to the extent that the Parent determines in good faith that such Dispositions are in the best interests of the Parent and the Borrowers and are not materially disadvantageous to the
Lenders, 
 (C) no Default or Event of Default shall exist immediately after giving effect thereto, and 
 (D) if the aggregate net book value of the assets sold, leased or otherwise disposed of in any single disposition (or in any series of
related dispositions) exceeds $5,000,000, the Borrower Representative shall have demonstrated compliance with the financial covenants hereunder on a Pro Forma Basis after giving effect to the disposition 

  

 10 

 
and shall have delivered to the Administrative Agent a Pro Forma Compliance Certificate (including reaffirmation of the representations and warranties
hereunder as of such date before and after giving effect to such transaction) demonstrating that, upon giving effect to such Asset Disposition on a Pro Forma Basis, the Credit Parties shall be in compliance with all of the covenants set forth in
Section 7.10; or 
 SUBPART 2.24 Amendment to Section 8.7(b). Subsection (b) of Section 8.7 of the
Existing Credit Agreement is hereby amended in its entirety to read as follows: 
 (b) RESERVED. 
 SUBPART 2.25 Amendment to Section 8.8. Section 8.8 of the Existing Credit Agreement is hereby amended in its entirety to read as
follows: 
 8.8 Transactions with Affiliates. 
 The Credit Parties will not permit any member of the Consolidated Group to enter into any transaction or series of transactions, whether
or not in the ordinary course of business, with any officer, director, shareholder, Subsidiary or Affiliate of such Person other than (a) transactions among the Credit Parties, (b) normal compensation and reimbursement of expenses of
officers and directors, (c) transactions relating to a Qualified Securitization Transaction and (d) except as otherwise specifically limited in this Credit Agreement, other transactions which are on terms and conditions substantially as
favorable to such Person as would be obtainable by it in a comparable arms-length transaction with a Person other than an officer, director, shareholder, Subsidiary or Affiliate and are either entered into in the ordinary course of such
Person’s business or approved by a majority of the Parent’s directors who are disinterested in the transaction. 
 SUBPART 2.26
Amendment to Section 8.12. Section 8.12 of the Existing Credit Agreement is hereby amended in its entirety to read as follows: 
 8.12 Restricted Payments. 
 The Credit Parties will not make, or permit any
member of the Consolidated Group to make, any Restricted Payment, unless (a) no Default or Event of Default shall exist immediately prior thereto and immediately after giving effect thereto and (b) in the case of any Restricted Payment
other than ordinary cash dividends, the Borrower Representative shall have delivered to the Administrative Agent a Pro Forma Compliance Certificate (including reaffirmation of the representations and warranties hereunder as of such date before and
after giving effect to such transaction) demonstrating that, upon giving effect to such Restricted Payment on a Pro Forma Basis, the Credit Parties shall be in compliance with all of the covenants set forth in Section 7.10; provided,
however, that if the Consolidated Total Leverage Ratio for the most recently tested fiscal quarter period is greater than 2.25 to 1.0, the aggregate amount expended to redeem, repurchase, retire or otherwise acquire the Parent’s common
stock during the Parent’s current fiscal year shall not exceed the greater of (i) $50,000,000 or (ii) the amount of redemptions and repurchases previously incurred during such fiscal year. 
  

 11 

 SUBPART 2.27 Amendment to Section 9.1(e). Subsection (e) of
Section 9.1 of the Existing Credit Agreement is hereby amended in its entirety to read as follows: 
 (e)
Guaranties. The guaranty given by any Guarantor (including any Additional Credit Party) hereunder or any material provision thereof shall cease to be in full force and effect, or any Guarantor (including any Additional Credit Party) or any
Person acting by or on behalf of such Guarantor shall deny or disaffirm such Guarantor’s obligations under such guaranty; or 
 SUBPART 2.28 Amendment to Section 9.1(h). Subsection (h) of Section 9.1 of the Existing Credit Agreement is hereby amended by deleting the reference to “$500,000” and replacing it with
“$10,000,000”.  
 SUBPART 2.29 Amendment to Section 11. Section 11 of the Existing Credit
Agreement is hereby amended to add the following as Subsection 11.18: 
 11.18 Replacement of Banks. If
any Bank requests compensation under Sections 3.6, 3.9 or 3.12, or if the obligation of any Bank to make or maintain Eurodollar Loans has been suspended under Section 3.8, or if the Borrower is required to pay any additional amount to any Bank
or any Governmental Authority for the account of any Bank pursuant to Section 3.11, or if any Bank is a Defaulting Bank, or if any Bank is a Non-Extending Bank, or if any Bank (a “Non-Consenting Bank”) refuses to consent to an
amendment, modification or waiver of this Agreement that, pursuant to Section 11.6, requires consent of 100% of the Banks or if any other circumstance exists hereunder that gives the Borrower the right to replace a Bank as a party hereto, then
the Borrower Representative may, at its sole expense and effort, upon 30 days notice to such Bank and the Administrative Agent, require such Bank to execute an Assignment and Assumption (the Administrative Agent being hereby authorized to execute
any Assignment and Assumption on behalf of such Bank relating to the assignment of Loans and/or Commitments of such Bank) within 60 days of such notice assigning and delegating, without recourse (in accordance with and subject to the restrictions
contained in, and consents required by, Section 11.3), all of its interests, rights and obligations under this Agreement and the related Loan Documents to an assignee that shall assume such obligations (which assignee may be another Bank, if a
Bank accepts such assignment), provided that: 
 (a) the Borrower shall have paid to the Administrative Agent the
assignment fee specified in Section 11.3; 
 (b) such Bank shall have received payment of an amount equal to the
outstanding principal of its Loans and its participation interests in the LOC Obligations and all other amounts payable to it hereunder and under the other Loan Documents (including any amounts under Section 3.12) from the assignee (to the
extent of such outstanding principal) or the Borrower (in the case of all other amounts). Any accrued interest and fees shall be paid pursuant to the provisions herein; 
  

 12 

 (c) in the case of any such assignment resulting from a claim for compensation under
Section 3.12 or payments required to be made pursuant to Section 3.11, such assignment will result in a reduction in such compensation or payments thereafter; 
 (d) in the event such Bank is a Non-Consenting Bank, each assignee shall consent, at the time of such assignment, to each matter in
respect of which such Bank was a Non-Consenting Bank; and 
 (e) such assignment does not conflict with applicable Laws.

 A Bank shall not be required to make any such assignment or delegation if, prior thereto, as a result of a waiver by such
Bank or otherwise, the circumstances entitling the Borrower to require such assignment and delegation cease to apply. Notwithstanding the foregoing, if the Borrower Representative (a) fails to give notice to the Administrative Agent and the
affected Bank of its intention to replace the affected Bank within thirty (30) days after the Bank requests compensation or indemnification, or (b) timely gives notice to the Administrative Agent and the affected Bank of its intention to
replace such affected Bank but does not so replace such affected Bank within sixty (60) days following such notice, then in each case the Borrowers’ rights under this Section 11.18 to replace such Bank for the particular circumstances
shall terminate. 
 SUBPART 2.30 The Existing Credit Agreement is hereby amended by deleting each reference to “Responsible
Officer of any Credit Party” and replacing it with “Responsible Officer”. 
 PART 3 
 CONSENT 
 SUBPART 3.1
Consent. The Administrative Agent and the Required Banks hereby consent to the release of Owens & Minor Healthcare Supply, Inc. (“O&M Healthcare”) and Access Diabetic Supply, Inc. (“Access”)
as Guarantors on the Third Amendment Effective Date pursuant to Section 10.11 of the Existing Credit Agreement. The Credit Parties acknowledge that O&M Healthcare and Access are not Material Guarantors. 
 PART 4 
 CONDITIONS TO EFFECTIVENESS

 SUBPART 4.1 Third Amendment Effective Date. This Amendment shall be and become effective as of the date hereof (the
“Third Amendment Effective Date”) in each case when all of the conditions set forth in this Part 4 shall have been satisfied, and thereafter this Amendment shall be known, and may be referred to, as the “Third
Amendment”. 
  

 13 

 SUBPART 4.2 Execution of Counterparts of Amendment. The Administrative Agent shall have
received counterparts of this Amendment, which collectively shall have been duly executed on behalf of each of the Borrowers, the Parent, the other Guarantors, the Required Banks and the Administrative Agent. 
 SUBPART 4.3 Officer's Certificates. The Administrative Agent shall have received a certificate or certificates executed by a Responsible
Officer of the Borrowers’ Representative as of the Third Amendment Effective Date, in form and substance satisfactory to the Administrative Agent, stating that (i) no Default or Event of Default exists and (ii) all representations and
warranties contained herein and in the other Credit Documents are true and correct in all material respects. 
 SUBPART 4.4 Fees
and Expenses. The Administrative Agent and each Bank signatory hereto shall have received from the Borrowers (i) the aggregate amount of fees and expenses payable in connection with the consummation of the transactions contemplated hereby
and (ii) all reasonable out-of-pocket costs and expenses of the Administrative Agent in connection with the preparation, execution and delivery of this Amendment (including without limitation, Moore & Van Allen PLLC, special counsel to
the Administrative Agent, shall have received from the Borrowers its reasonable fees and expenses incurred in connection with the preparation, execution and delivery of this Amendment). 
 PART 5 
 MISCELLANEOUS 
 SUBPART 5.1 Representations and Warranties. The Borrowers hereby represent and warrant to the Administrative Agent and the Required Banks
that, after giving effect to this Amendment, (a) no Default or Event of Default exists under the Credit Agreement and (b) the representations and warranties set forth in Section 6 of the Existing Credit Agreement are, subject to the
limitations set forth therein, true and correct in all material respects as of the date hereof (except for those which expressly relate to an earlier date, in which case, they are true and correct in all material respects as of such earlier date).

 SUBPART 5.2 Cross-References. References in this Amendment to any Part or Subpart are, unless otherwise specified, to such
Part or Subpart of this Amendment. 
 SUBPART 5.3 Instrument Pursuant to Existing Credit Agreement. This Amendment is executed
pursuant to the Existing Credit Agreement and shall (unless otherwise expressly indicated therein) be construed, administered and applied in accordance with the terms and provisions of the Existing Credit Agreement. 
 SUBPART 5.4 References in Other Credit Documents. At such time as this Amendment shall become effective pursuant to the terms of Subpart
4.1, all references to the “Credit Agreement” shall be deemed to refer to the Credit Agreement as amended by this Amendment. 
  

 14 

 SUBPART 5.5 Counterparts/Telecopy. This Amendment may be executed by the parties hereto in
several counterparts, each of which shall be deemed to be an original and all of which shall constitute together but one and the same agreement. Delivery of executed counterparts of the Amendment by telecopy shall be effective as an original and
shall constitute a representation that an original shall be delivered. 
 SUBPART 5.6 Governing Law. THIS AMENDMENT SHALL BE
DEEMED TO BE A CONTRACT MADE UNDER AND GOVERNED BY THE INTERNAL LAWS OF THE COMMONWEALTH OF VIRGINIA. 
 SUBPART 5.7 Successors and
Assigns. This Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns. 
 SUBPART 5.8 General. Except as amended hereby, the Existing Credit Agreement and all other credit documents shall continue in full force and effect. 
 [Remainder of Page Intentionally Left Blank] 
  

 15 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amendment and Consent to Amended
and Restated Credit Agreement as of the date first above written. 
  

					
	BORROWERS:	 	OWENS & MINOR MEDICAL, INC.,
		 	a Virginia corporation
			
		 	By:	  	  

		 	Name:	  	  

		 	Title:	  	  

		
		 	OWENS & MINOR DISTRIBUTION, INC.,
		 	a Virginia corporation
			
		 	By:	  	  

		 	Name:	  	  

		 	Title:	  	  

		
	GUARANTORS:	 	OWENS & MINOR, INC.,
		 	a Virginia corporation
			
		 	By:	  	  

		 	Name:	  	  

		 	Title:	  	  

		
		 	OWENS & MINOR HEALTHCARE SUPPLY, INC.,
		 	a Virginia corporation
			
		 	By:	  	  

		 	Name:	  	  

		 	Title:	  	  

		
		 	ACCESS DIABETIC SUPPLY, LLC,
		 	a Florida limited liability company
			
		 	By:	  	  

		 	Name:	  	  

		 	Title:	  	  

  

 16 

					
	ADMINISTRATIVE AGENT:	 	BANK OF AMERICA, N.A.,
		 	in its capacity as Administrative Agent
			
		 	By:	  	  

		 	Name:	  	  

		 	Title:	  	  

		
	BANKS:	 	BANK OF AMERICA, N.A.,
		 	as a Bank
			
		 	By:	  	  

		 	Name:	  	  

		 	Title:	  	  

  

 17 

					
		 	 SUNTRUST BANK,
 as a
Bank

			
		 	By:	  	  

		 	Name:	  	  

		 	Title:	  	  

  

 18 

					
		 	 WACHOVIA BANK, NATIONAL ASSOCIATION,
 as a Bank

			
		 	By:	  	  

		 	Name:	  	  

		 	Title:	  	  

  

 19 

					
		 	 KEYBANK NATIONAL ASSOCIATION,
 as a
Bank

			
		 	By:	  	  

		 	Name:	  	  

		 	Title:	  	  

  

 20 

					
		 	 LEHMAN COMMERCIAL PAPER INC.,
 as a
Bank

			
		 	By:	  	  

		 	Name:	  	  

		 	Title:	  	  

  

 21 

					
		 	 UNION BANK OF CALIFORNIA, N.A.,
 as
a Bank

			
		 	By:	  	  

		 	Name:	  	  

		 	Title:	  	  

  

 22 

					
		 	 COMERICA BANK,
 as a
Bank

			
		 	By:	  	  

		 	Name:	  	  

		 	Title:	  	  

  

 23 

					
		 	 U.S. BANK, NATIONAL ASSOCIATION,
 as a Bank

			
		 	By:	  	  

		 	Name:	  	  

		 	Title:	  	  

  

 24 

					
		 	 THE BANK OF NEW YORK,
 as a Bank

			
		 	By:	  	  

		 	Name:	  	  

		 	Title:	  	  

  

 25 

					
		 	 FIFTH THIRD BANK,
 as a
Bank

			
		 	By:	  	  

		 	Name:	  	  

		 	Title:	  	  

  

 26 

					
		 	 CITIBANK N.A.,
 as a
Bank

			
		 	By:	  	  

		 	Name:	  	  

		 	Title:	  	  

  

 27Separation Agreement, dated July 15, 2008--Joshua Schein

 Exhibit 10.4 
 LEV PHARMACEUTICALS, INC. 
 675 Third Avenue 
 Suite 2200 
 New York, NY 10017 
 July 15, 2008 
 Dr. Joshua Schein 
 c/o Lev Pharmaceuticals, Inc. 
 675 Third Avenue 
 Suite 2200 
 New York, NY 10017 
 Dear Dr. Schein: 
 Reference is made to the Agreement
and Plan of Merger by and among ViroPharma Incorporated (“Buyer”), HAE Acquisition Corp (“Sub”), and Lev Pharmaceuticals, Inc. (the “Company”), dated July 15, 2008 (the “Merger Agreement”) and the
Second Amended and Restated Employment Agreement between you and the Company dated December 20, 2007 (the “Employment Agreement”). Unless otherwise specified herein, capitalized terms used herein without definition have the
meanings ascribed in the Merger Agreement or the Employment Agreement, as applicable. 
 This letter agreement (the
“Agreement”) sets forth our mutual agreement concerning (i) your resignation as an executive officer and employee of the Company effective immediately after the closing of the transactions (the “Merger”)
contemplated by the Merger Agreement (the “Closing”), (ii) the payments that will be made to you and (iii) amends the restrictions on competition set forth in the Employment Agreement. 
 1. Resignation. Your employment with the Company and its subsidiaries and affiliates will terminate in all capacities immediately after the Closing
(the “Effective Time”). 
 2. Payments. The Company will provide you with the following payments and benefits:

 (a) An amount equal to $14,365,000, which represents 3.25% of the Enterprise Value ($442,000,001) of the Company without regard to the
Contingent Value Rights issued in connection with the Merger (such amount being, the “Total Transaction Amount”). The Total Transaction Amount shall be paid as follows: 
 (i) That portion of the Total Transaction Amount which is attributable to the Transaction Fee, or $6,630,000, shall be paid in a lump sum,
subject to receipt by the Company and Buyer of a mutual release in the form attached hereto signed by You, on the Closing Date. 
 (ii) That portion of the Total Transaction Amount which is attributable to the severance amounts payable to you pursuant to Section 8(b) of the Employment Agreement (the “Severance Amount”) shall be paid in a lump sum
on the day after the six-month period starting on the date of Closing. To illustrate, if the Closing occurs on September 30, 2008, the Severance Amount would be $6,377,823 and the payment will be made on March 31, 2009. 

 (iii) The remaining portion of the Total Transaction Amount (less the parties good faith
determination of the cost of the benefits provided in Section 2(c) below) which is attributable to the Gross-Up Payment described in Section 8(e) of the Employment Agreement (the “Gross-Up Amount”) shall be paid to you
when such taxes are remitted but in no event later than the last day of the taxable year following the taxable year in which you are required to pay the Excise Tax. 
 In accordance with Section 8(c) of the Employment Agreement, subject to receipt by the Company and Buyer of a mutual release in the form attached hereto signed by You, on the Closing Date the Company will place
the Severance Amount and the Gross-Up Amount into a “rabbi trust.” Such trust shall be maintained pursuant to a standard rabbi trust arrangement by and among you, the Company, and an independent trustee providing for the timely payment of
the amounts held in the trust (the “Trust Arrangement”). The Trust Arrangement shall be maintained until all sums held in the trust have been paid. 
 (b) As soon as practicable following, but in no event more than thirty (30) days following, the date that the First CVR Payment Amount is deemed earned, the Enterprise Value shall be increased to $522,363,637 and
the Buyer shall pay you an additional amount equal to $1,205,455 as an additional Transaction Fee payment on such date. As soon as practicable following, but in no event more than thirty (30) days following, the date that the Second CVR Payment
Amount is deemed earned, the Enterprise Value will increase to $602,727,274 and the Buyer shall pay you an additional amount equal to $1,205,455 as an additional Transaction Fee payment on such date. Any additional Gross-Up Payments applicable to
each additional Transaction Fee payments and to the payment of the CVRs up to the applicable Cap (which in each case increases by $2,611,818) shall be paid by the Company within the time specified in Section 2(a)(iii) above. The first CVR
Payment Amount and the Second CVR Payment Amount shall not be subject to the rabbi trust provisions described above and shall be paid in accordance with this Section 2(b). 
 (c) Continuation of Insurance Coverage. As provided in Section 7(e)(ii)(B) of the Employment Agreement, the Company or the Buyer will
continue (or provide comparable substitute coverage) your health, dental, disability and life insurance coverage as in effect on the date of your termination, and pay the applicable premiums, until the earlier of (a) December 31, 2012 or
(b) the date on which you are covered under another comparable plan. You agree to notify the Company in writing within 15 (fifteen) days in the event that you obtain coverage under another such plan. 
 (d) 401(k) Plan. You will be entitled to receive your vested accrued benefits under the Company’s 401(k) plan in accordance with the terms
and conditions of such plan. 
 (e) Options; Restricted Stock. Your options to purchase the Company’s Common stock and your
restricted shares of Common Stock will be deemed fully vested at the Closing and will be treated as contemplated in the Merger Agreement. 
 (f) Accrued Compensation. You shall also be entitled to receive the Accrued Compensation in accordance with the Employment Agreement. 
  

 - 2 - 

 3. Restrictive Covenants. 
 (a) Non-competition. Effective as of the Closing, Section 9(d) of the Employment Agreement is amended in its entirety to read as follows:

 “Schein agrees that during the period beginning on the Closing Date and ending three years after the Closing Date (the
“Noncompete Restricted Period”), he shall not, except for a Permitted Activity, directly or indirectly, for his own benefit or for the benefit of any other person or entity (whether as an officer, director, employee, partner,
joint venturer, consultant, investor or otherwise): 
  

	 	(i)	Engage in direct competition with the Business (as defined below); 

  

	 	(ii)	Solicit, encourage or induce any person or entity, or any affiliate of any person or entity, which, as of the Closing Date is a vendor or customer of the Company, to sever its, or
not enter into a, or reduce a, relationship with the Company, Sub or Buyer relating to the Business; or 

  

	 	(iii)	For purposes hereof, the term “Business” shall mean the development and commercialization of therapeutic products for the (x) sole and primary purpose
of the treatment and/or prevention of hereditary angioedema and/or (y) involving a human C-1 esterase inhibitor. 

 For purposes hereof,
“Permitted Activity” means (i) the ownership of publicly-traded securities of any entity not exceeding 3% of the total amount outstanding of such securities, (ii) following Schein’s notice to Buyer, the direct
employment with a government entity or university (or contracting relationship with such an entity or university solely as an individual contributor) other than work performed for a university that directly benefits a competitor of the Company or is
performed in connection with a project the subject matter of which is in direct competition with the products or services offered by the Company as of the Closing Date or (iii) accepting employment (or performing services for) any entity whose
business is diversified but which engages in the Business, so long as (A) Schein does not render any services or assistance to any division or part of such entity that is in any way engaged in the Business, and (B) Buyer shall have
received, prior to Schein rendering any services or assistance, written assurance from such entity that Schein shall not render any services or assistance to any division or part of such entity that is in any way engaged in the Business; provided
that the Permitted Activity does not include (a) any operational management position in any such entity referenced in (i) above or (b) any activity described in Section 9(d)(ii) above. 
 (b) Non-solicitation of Employees. Effective as of the Closing, Section 9(e) of the Employment Agreement is amended in its entirety to read
as follows: 
 “Schein agrees that during the period beginning on the Closing Date and ending one year after the Closing
Date, he shall not (i) solicit for employment or recruit (whether as an employee, principal, consultant or otherwise) any person who is an employee of or consultant to the Company immediately prior to the Closing Date, or (ii) induce or
encourage any such person to sever his/her relationship with the Company or Buyer; provided, that the provisions of this Section 9(e) shall not be violated if such employee or consultant or former employee or consultant (x) responds to a
general advertisement for services not specifically directed at such person, or (y) has been terminated by the Company or the Buyer. This provision shall not apply to Judson Cooper.” 
  

 - 3 - 

 (c) Notwithstanding anything to the contrary, you shall not be required to comply with any provision of
Sections 9(d) or 9(e) of the Employment Agreement if the amounts required to be paid pursuant to Section 2 of this Agreement are not timely paid. 
 4. Communications. You and the Buyer agree that the press release and any related statements regarding your resignation will be in the form to be mutually agreed upon, and that no subsequent comments should be
made to the media or through other public statements by either party or by any subsidiary, officer or director of the Buyer regarding your departure that are inconsistent with such statement. From and after the Effective Time, you will refrain from
taking actions or making public statements, written or oral, which denigrate, disparage or defame the goodwill or reputation of the Buyer and its subsidiaries and their former and current executive officers and directors. From and after the
Effective Time, the Buyer will refrain, and will cause its executive officers and directors to refrain, from taking actions or making public statements, written or oral, which denigrate, disparage or defame your reputation. The restrictions set
forth in this Section 4 will be subject to such exceptions as are required by law or in connection with a judicial proceeding. 
 5.
Release. On or prior to the Closing Date, You, the Company, and the Buyer will enter into a mutual release in the form attached hereto. 
 6. Indemnification. The Buyer shall continue to provide, and shall cause its subsidiaries to continue to provide you with indemnification, expense advancement, exculpation of liabilities and directors and officers liability
insurance, with respect to actions or inactions by you as an officer or director of the Company (or any of its subsidiaries) prior to the Effective Time to the fullest extent permitted by law. 
 7. No Set-Off or Mitigation. The Company’s and/or the Buyer’s obligations to make the payments provided for in this Agreement and
otherwise to perform its obligations hereunder shall not be affected by any set-off, counterclaim, recoupment, defense or other claim, right or action which the Company may have against you or others. In no event shall you be obligated to seek other
employment or take any other action by way of mitigation of the amounts payable to you under any of the provisions of this Agreement, and such amounts shall not be reduced whether or not you obtain other employment (other than the obligation to
continue benefits coverage as provided in Section 2(b) above). 
 8. Miscellaneous. 
 (a) Effect on Employment Agreement. Except as set forth herein, the Employment Agreement remains in full force and effect. In the event that the
Merger has not been consummated prior to the Expiration Date (as defined in the Merger Agreement), this Agreement shall be null, void and of no further force and effect. 
 (b) Taxes. Any payments made or benefits provided to you under this Agreement will be reduced by any applicable federal and state withholding and employment taxes. Nothing herein shall amend the provisions of
the Employment Agreement that relate to the determination as to whether an Excise Tax is due and the amount of such Excise Tax. 
 (c)
Survival of Provisions. The following sections of the Employment Agreement shall survive the termination of your employment, Sections 8 (as clarified and modified herein), 9 (as modified herein), 10, 11, 12, 14, 17, 19, 21, and 22.

 (d) Legal Expenses. The Company will pay the legal fees incurred by you in connection with the Merger. 
  

 - 4 - 

 (e) Enforceability/Severability. The parties hereto affirmatively acknowledge that this
Agreement, and each of its provisions, is enforceable, and expressly agree not to challenge nor raise any defense against the enforceability of this Agreement or any of its provisions in the future. The invalidity or unenforceability of any
provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement. In the event that any provision or portion of this Agreement shall be determined to be invalid or unenforceable for any reason, the
remaining provisions or portions of this Agreement shall be unaffected thereby and shall remain in full force and effect to the fullest extent permitted by law. 
 (f) Successors. This Agreement shall be binding on you and the Company and your’s and the Company’s respective heirs, successors and assigns, including without limitation, the Buyer. Your obligations
under this Agreement may not be assigned. The obligations of the Company under this Agreement may not be assigned except to a successor to all or substantially all of the business or assets of the Company or by operation of law. In the event of your
death, all future payments hereunder will be made to your estate or designated beneficiary. 
 (g) Injunctive Relief. Notwithstanding
anything to the contrary in the Employment Agreement, any breach of the restrictive covenant obligations, including any breach of the non-competition or non-solicitation provisions shall be subject to the remedy provisions, including injunctive
relief enforced by a court of competent jurisdiction, of Section 9(f) of the Employment Agreement. 
  

			
	LEV PHARMACEUTICALS, INC.
		
	By	 	 /s/ Judson Cooper

	Name:	 	Judson Cooper
	Title:	 	Chairman
	Dated:	 	7/15/08

  

	
	Accepted and Agreed:
	
	 /s/ Joshua Schein

	Dr. Joshua Schein
	Dated: 7/15/08

  

			
	ACKNOWLEDGED AND AGREED IN ALL RESPECTS
	
	ViroPharma Incorporated
		
	By	 	 /s/ Vincent J. Milano

	Name:	 	
	Title:	 	
	Dated:	 	  

  

 - 5 - 

 Annex A 
 FORM OF RELEASE 
 GENERAL RELEASE AGREEMENT 
 This is a General Release Agreement (“General Release”) between Joshua Schein (“You”), Lev
Pharmaceuticals, Inc., (“the Company”) and ViroPharma Incorporated (“Buyer”). 
 (a) General Release. In consideration of
the Company’s obligations under the Agreement dated July 15, 2008 between Lev Pharmaceuticals, Inc., (“the Company”) and ViroPharma Incorporated (“Buyer”) (the “Agreement”) and for other valuable
consideration, You hereby release and forever discharge the Company, its subsidiaries and affiliates and each of their respective officers, employees, directors and agents (the “Company Releases”) from any and all claims, actions
and causes of action (collectively, “Claims”), including, without limitation, any Claims arising under any applicable federal, state, local or foreign law, that You may have, or in the future may possess, arising out of
(x) your employment relationship with and service as a director, employee or officer of the Company or any of its subsidiaries or affiliates, and the termination of such relationship or service, or (y) any event, condition, circumstance or
obligation that occurred, existed or arose on or prior to the date hereof; provided, however, that the release set forth herein will not apply to (A) the obligations of the Company under the Agreement and the Employment Agreement
and Merger Agreement referenced therein. You further agree that the payments and benefits described in the Agreement will be in full satisfaction of any and all claims for payments or benefits, whether express or implied, that You may have against
the Company or any of its subsidiaries or affiliates arising out of your employment relationship, your service as a director, employee or officer of the Company or any of its subsidiaries or affiliates and the termination thereof. You hereby
acknowledge and confirm that You are providing the release and discharge set forth herein only in exchange for consideration in addition to anything of value to which You are already entitled. You acknowledge and agree that if You should hereafter
make any claim or demand or commence or threaten to commence any action, claim or proceeding against the Company Releases with respect to any cause, matter or thing which is the subject of this Section 8(a), this General Release may be raised
as a complete bar to any such action, claim or proceeding, and the applicable Company Release may recover from You all costs incurred in connection with such action, claim or proceeding, including attorneys’ fees. This is a General Release
except as set forth herein. By signing this General Release, You are agreeing to forego all claims or potential claims against the Company except as set forth herein. You agree that this release will extinguish all claims which have arisen at any
time up to the time You sign this General Release. 
 (b) Release of Unknown Claims. You understand and agree that the claims released herein by
You are intended to and do include any and all claims of every nature and kind whatsoever, known or unknown, suspected or unsuspected, which You have or may have against any person or entity You released above and You expressly consent that this
General Release shall be given 

  

 - 6 - 

 
full force and effect according to each and all of its expressed terms and provisions, including as well those relating to unknown and unspecified claims,
charges, demands, suits, actions, causes of action and debts, if any, and those relating to any other claims, charges, demands, suits, actions, causes of action and debts hereinabove specified. You acknowledge that You are aware that You may
hereafter discover claims or facts in addition to, or different from, those which You now know or believe to exist with respect to the subject matter covered by this General Release and which, if known or suspected at the time of executing this
General Release, may have materially affected this General Release or your decision to enter into it. Nevertheless, You hereby waive any rights, claims or causes of action that might arise as a result of such different or additional claims or facts.
You agree not to file, join in or prosecute further any lawsuits against the Company, concerning any matter in any way arising out of or relating in any way to any matter, act, occurrence, omission, practice, conduct, policy, event, or transaction
on or before the date of this General Release. By signing this General Release, You agree not to sue the Company with respect to any claims that have been released herein. You expressly represent that as of the date that You sign this General
Release, You have no pending grievances, claims, complaints, administrative charges or lawsuits against the Company or any other released party. 
 (c)
Releases: Without limiting the generality of the General Release, You specifically acknowledge and agree that, except as set forth herein, You are knowingly and voluntarily releasing each and all of the following persons, companies, and
entities from any and all claims You have or may have: Lev Pharmaceuticals, Inc. and ViroPharma Incorporated and any and all past, present, and/or future parent, subsidiary, affiliate, related business entity, employee benefit plan or fund, and its
and their respective past, present, and/or future officers, directors, employees, agents, predecessors, successors, purchasers, attorneys, assigns, and representatives. 
 (d) Company Release. The Company and its subsidiaries and affiliates, including, without limitation, the Buyer (the “Company Releasors”) hereby release and forever discharge You, your estate
and your legal representatives (the “Individual Releases”) from any and all known and unknown Claims, including, without limitation, any Claims arising under any applicable federal, state, local or foreign law, that it may have, or
in the future may possess, arising out of (x) your employment relationship with and service as a director, employee or officer of the Company or any of its subsidiaries or affiliates or predecessors, and the termination of such relationship or
service, or (y) any event, condition, circumstance or obligation that occurred, existed or arose on or prior to the date hereof; provided, however, that the release set forth herein will not apply to your obligations under this
Agreement. The Company acknowledges and agrees that if it or any other Company Releasor should hereafter make any claim or demand or commence or threaten to commence any action, claim or proceeding against You or the Individual Releases with respect
to any cause, matter or thing which is the subject of this Section, this Agreement may be raised as a complete bar to any such action, claim or proceeding, and You or the applicable Individual Release may recover from the Company Releasors all costs
incurred in connection with such action, claim or proceeding, including attorneys’ fees. 
 (e) No Waiver: The Parties recognize, acknowledge and
agree that the failure by a Party to enforce any term of this General Release shall not constitute a waiver of any rights or deprive the Party of the right to insist thereafter upon strict adherence to that or any other term of this General Release,
nor shall a waiver of any breach of this General Release constitute a waiver of any preceding or succeeding breach. No waiver of a right under any provision of this General Release shall be binding unless made in writing and signed by the Party.

  

 - 7 - 

 (f) Miscellaneous: The validity and construction of this General Release or of any of its terms or provisions
shall be determined under the laws of the State of New York, regardless of any principles of conflicts of laws or choice of laws of any jurisdiction. You represent and warrant that no person had or has or claims any interest in the claims referred
to anywhere in this General Release. You also represent and warrant that You have not heretofore assigned or transferred, or purported to assign or transfer, to any person or entity, any claim against the Company or portion thereof or interest
therein, and will not assign or otherwise transfer, any claim or demand relating to any matter covered by this General Release or the consideration to be paid pursuant thereto. The Parties agree that this General Release shall inure to the benefit
of the officers, directors, employees, agents, parents, affiliates, predecessors, successors, purchasers, assigns, and representatives of the Company. The Parties agree that this General Release shall not be modified, waived or amended except in
writing signed by each of the Parties. 
 (g) Consultation with Attorney: You acknowledge that You have been advised by the Company to consult an
attorney regarding the terms of this General Release before signing it, and state that You have consulted with your attorney regarding this General Release, and that in executing this General Release You have not relied upon any representations or
statements by the Company or any of its respective agents, representatives, employees, or attorneys regarding the subject matter, basis, or effect of this General Release. 
 JOSHUA SCHEIN REPRESENTS THAT HE HAS READ THIS GENERAL RELEASE, THAT BASED THEREON, HE UNDERSTANDS ALL OF ITS TERMS, AND THAT HE ENTERS INTO THIS GENERAL RELEASE VOLUNTARILY AND WITH FULL KNOWLEDGE OF ITS EFFECT.

  

							
	  
	 		 		 	  

	Date	 		 		 	Signature
			
		 		 	LEV PHARMACEUTICALS, INC.
				
	  
	 		 	By:	 	  

	Date	 		 		 	
			
		 		 	VIROPHARMA INCORPORATED
				
	  
	 		 	By:	 	  

	Date	 		 		 	

  

 - 8 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}]]